Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.